Jump to content

Lirequinil: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m Added 2 dois to journal cites using AWB (10102)
No edit summary
Line 48: Line 48:
| smiles = CCO[C@H]1CCN(C1)C(=O)C2=C3C4=C(CCN3C(=O)C(=C2)C5=CC=CC=C5)C=CC(=C4)Cl
| smiles = CCO[C@H]1CCN(C1)C(=O)C2=C3C4=C(CCN3C(=O)C(=C2)C5=CC=CC=C5)C=CC(=C4)Cl
}}
}}

'''Lirequinil''' ('''Ro41-3696''') is a [[nonbenzodiazepine]] [[hypnotic]] drug which binds to benzodiazepine sites on the [[GABAA receptor|GABA<sub>A</sub>]] [[Receptor (biochemistry)|receptor]]. In human [[clinical trials]], lirequinil was found to have similar efficacy to [[zolpidem]], with less side effects such as clumsiness and memory impairment. However it was also much slower acting than zolpidem, with peak plasma concentrations not reached until 2.5 hours after oral administration, and its O-desethyl metabolite Ro41-3290 is also active with a half-life of 8 hours.<ref name="pmid8522640">{{cite journal |author=Dingemanse J, Bury M, Roncari G, Zell M, Gieschke R, Gaillard AW, Odink J, van Brummelen P |title=Pharmacokinetics and pharmacodynamics of Ro 41-3696, a novel nonbenzodiazepine hypnotic |journal=Journal of Clinical Pharmacology |volume=35 |issue=8 |pages=821–9 |date=August 1995 |pmid=8522640 |doi= 10.1002/j.1552-4604.1995.tb04126.x|url=}}</ref><ref name="pmid8848532">{{cite journal |author=Dingemanse J, Bury M, Bock J, Joubert P |title=Comparative pharmacodynamics of Ro 41-3696, a new hypnotic, and zolpidem after night-time administration to healthy subjects |journal=Psychopharmacology |volume=122 |issue=2 |pages=169–74 |date=November 1995 |pmid=8848532 |doi= 10.1007/BF02246091|url=}}</ref><ref name="pmid11095577">{{cite journal |author=Dingemanse J, Bury M, Hussain Y, van Giersbergen P |title=Comparative tolerability, pharmacodynamics, and pharmacokinetics of a metabolite of a quinolizinone hypnotic and zolpidem in healthy subjects |journal=Drug Metabolism and Disposition: the Biological Fate of Chemicals |volume=28 |issue=12 |pages=1411–6 |date=December 2000 |pmid=11095577 |doi= |url=}}</ref><ref name="pmid11307042">{{cite journal |author=Dingemanse J, Pedrazzetti E, van Giersbergen PL |title=Multiple-dose tolerability, pharmacodynamics, and pharmacokinetics of the quinolizinone hypnotic Ro 41-3696 in elderly subjects |journal=Clinical Neuropharmacology |volume=24 |issue=2 |pages=82–90 |year=2001 |pmid=11307042 |doi= 10.1097/00002826-200103000-00003|url=}}</ref> This meant that while effective as a hypnotic, lirequinil failed to prove superior to zolpidem due to producing more next-day sedation, and it has not been adopted for clinical use. It was developed by a team at Hoffmann-La Roche in the 1990s.<ref>US Patent 5561233 Process for the preparation of an intermediate of a benzo[a]quinolizinone derivative</ref>
'''Lirequinil''' ('''Ro41-3696''') is a [[nonbenzodiazepine]] [[hypnotic]] drug which binds to benzodiazepine sites on the [[GABAA receptor|GABA<sub>A</sub>]] [[Receptor (biochemistry)|receptor]]. In human [[clinical trials]], lirequinil was found to have similar efficacy to [[zolpidem]], with less side effects such as clumsiness and memory impairment. However it was also much slower acting than zolpidem, with peak plasma concentrations not reached until 2.5 hours after oral administration, and its O-desethyl metabolite Ro41-3290 is also active with a half-life of 8 hours.<ref name="pmid8522640">{{cite journal |author=Dingemanse J, Bury M, Roncari G, Zell M, Gieschke R, Gaillard AW, Odink J, van Brummelen P |title=Pharmacokinetics and pharmacodynamics of Ro 41-3696, a novel nonbenzodiazepine hypnotic |journal=Journal of Clinical Pharmacology |volume=35 |issue=8 |pages=821–9 |date=August 1995 |pmid=8522640 |doi= 10.1002/j.1552-4604.1995.tb04126.x|url=}}</ref><ref name="pmid8848532">{{cite journal |author=Dingemanse J, Bury M, Bock J, Joubert P |title=Comparative pharmacodynamics of Ro 41-3696, a new hypnotic, and zolpidem after night-time administration to healthy subjects |journal=Psychopharmacology |volume=122 |issue=2 |pages=169–74 |date=November 1995 |pmid=8848532 |doi= 10.1007/BF02246091|url=}}</ref><ref name="pmid11095577">{{cite journal |author=Dingemanse J, Bury M, Hussain Y, van Giersbergen P |title=Comparative tolerability, pharmacodynamics, and pharmacokinetics of a metabolite of a quinolizinone hypnotic and zolpidem in healthy subjects |journal=Drug Metabolism and Disposition: the Biological Fate of Chemicals |volume=28 |issue=12 |pages=1411–6 |date=December 2000 |pmid=11095577 |doi= |url=}}</ref><ref name="pmid11307042">{{cite journal |author=Dingemanse J, Pedrazzetti E, van Giersbergen PL |title=Multiple-dose tolerability, pharmacodynamics, and pharmacokinetics of the quinolizinone hypnotic Ro 41-3696 in elderly subjects |journal=Clinical Neuropharmacology |volume=24 |issue=2 |pages=82–90 |year=2001 |pmid=11307042 |doi= 10.1097/00002826-200103000-00003|url=}}</ref> This meant that while effective as a hypnotic, lirequinil failed to prove superior to zolpidem due to producing more next-day sedation, and it has not been adopted for clinical use. It was developed by a team at Hoffmann-La Roche in the 1990s.<ref>US Patent 5561233 Process for the preparation of an intermediate of a benzo[a]quinolizinone derivative</ref>


Line 54: Line 55:
==References==
==References==
{{reflist}}
{{reflist}}



{{Hypnotics}}
{{Hypnotics}}
{{GABAAergics}}
{{GABAAR PAMs}}


[[Category:Sedatives]]
[[Category:Sedatives]]
[[Category:GABAA receptor positive allosteric modulators]]

Revision as of 12:59, 11 November 2014

Lirequinil
Clinical data
ATC code
  • none
Identifiers
  • 10-chloro-1-[(3S)-3-ethoxypyrrolidine-1-carbonyl]-3-phenyl-6,7-dihydrobenzo[a]quinolizin-4-one
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC26H25ClN2O3
Molar mass448.941 g/mol g·mol−1
3D model (JSmol)
  • CCO[C@H]1CCN(C1)C(=O)C2=C3C4=C(CCN3C(=O)C(=C2)C5=CC=CC=C5)C=CC(=C4)Cl
  • InChI=1S/C26H25ClN2O3/c1-2-32-20-11-12-28(16-20)25(30)23-15-22(17-6-4-3-5-7-17)26(31)29-13-10-18-8-9-19(27)14-21(18)24(23)29/h3-9,14-15,20H,2,10-13,16H2,1H3/t20-/m0/s1 ☒N
  • Key:CBSWRAUYCIIUEI-FQEVSTJZSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Lirequinil (Ro41-3696) is a nonbenzodiazepine hypnotic drug which binds to benzodiazepine sites on the GABAA receptor. In human clinical trials, lirequinil was found to have similar efficacy to zolpidem, with less side effects such as clumsiness and memory impairment. However it was also much slower acting than zolpidem, with peak plasma concentrations not reached until 2.5 hours after oral administration, and its O-desethyl metabolite Ro41-3290 is also active with a half-life of 8 hours.[1][2][3][4] This meant that while effective as a hypnotic, lirequinil failed to prove superior to zolpidem due to producing more next-day sedation, and it has not been adopted for clinical use. It was developed by a team at Hoffmann-La Roche in the 1990s.[5]

Active metabolite Ro41-3290

References

  1. ^ Dingemanse J, Bury M, Roncari G, Zell M, Gieschke R, Gaillard AW, Odink J, van Brummelen P (August 1995). "Pharmacokinetics and pharmacodynamics of Ro 41-3696, a novel nonbenzodiazepine hypnotic". Journal of Clinical Pharmacology. 35 (8): 821–9. doi:10.1002/j.1552-4604.1995.tb04126.x. PMID 8522640.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  2. ^ Dingemanse J, Bury M, Bock J, Joubert P (November 1995). "Comparative pharmacodynamics of Ro 41-3696, a new hypnotic, and zolpidem after night-time administration to healthy subjects". Psychopharmacology. 122 (2): 169–74. doi:10.1007/BF02246091. PMID 8848532.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ Dingemanse J, Bury M, Hussain Y, van Giersbergen P (December 2000). "Comparative tolerability, pharmacodynamics, and pharmacokinetics of a metabolite of a quinolizinone hypnotic and zolpidem in healthy subjects". Drug Metabolism and Disposition: the Biological Fate of Chemicals. 28 (12): 1411–6. PMID 11095577.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ^ Dingemanse J, Pedrazzetti E, van Giersbergen PL (2001). "Multiple-dose tolerability, pharmacodynamics, and pharmacokinetics of the quinolizinone hypnotic Ro 41-3696 in elderly subjects". Clinical Neuropharmacology. 24 (2): 82–90. doi:10.1097/00002826-200103000-00003. PMID 11307042.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ^ US Patent 5561233 Process for the preparation of an intermediate of a benzo[a]quinolizinone derivative


Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Lirequinil&oldid=633375502"